Soft Tissue Infection
Conditions
Interventions
Control group:Commonly used clinical therapies are as follows:
1) Subjects underwent debridement to remove fibrous tissue and necrotic tissue
2) Wrap the wound with sterile gauze and change the dressing every other day.
3) Adjust the antibiotic regimen based on blood inflammation indicators.
Experimental group:Commonly used clinical therapies and Drug-loaded nano-peripheral blood extract treatment are as follows:
1) The nurse collects venous blood according to standard operating procedure
Sponsors
Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. The patient has one of the following clinical symptoms: a) local skin redness, swelling and pain; b) skin ulcers and necrosis; c) Skin temperature =38?. 2. Diagnosis of soft tissue infection with one of the following categories: a) Open full-thickness wound (such as postoperative wound cracking, healing Adverse wounds, diabetic foot ulcers, pressure injuries, traumatic wounds) combined with infection; b) Primary osteomyelitis or postoperative bone infection combined and soft tissue infection. 3. Microbiologically confirmed bacterial infection. 4. =18 years old. 5. Voluntarily participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Life expectancy is less than 1 year. 2. Multiple organ failure. 3. Staphylococcus aureus bacteremia occurs or has occurred within one month. 4. Endocarditis occurs or has occurred within one month. 5. Infections without appropriate antibiotic treatment. 6. Presence of clinical, histological, or microbiological evidence of mycobacterial, fungal, parasitic, or viral infection. 7. Insufficient blood supply to blood vessels (ankle-brachial index ABI1.3). 8. Revascularization in the last 6 weeks. 9. Major medical conditions that impair wound healing, such as aplastic anemia, liver disease, scleroderma, and malignant tumors or immunosuppressive therapy. 10. Patients who are participating in other clinical studies. 11. The specimen collection situation is not ideal. 12. Vulnerable groups, including people with mental illness, cognitive impairment, critically ill patients, pregnant women, illiterates, etc. 13. Those who the researcher believes are not suitable to participate in this study for other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Wound area; | — |
Secondary
| Measure | Time frame |
|---|---|
| RNA sequence;Immunofluorescence;bacteria count;Blood inflammation indicators; | — |
Countries
China
Contacts
Public ContactLin Xianfeng
Sir Run Run Shaw Hospital, Medical College of Zhejiang University
Outcome results
None listed